Literature DB >> 7446620

Second-look operations in ovarian cancer.

P E Schwartz, J P Smith.   

Abstract

One hundred eighty-six patients with epithelial tumors of the ovary who were managed at the M. D. Anderson Hospital and Tumor Institute underwent an exploratory operation ("second-look" operation) to assess the status of the cancer. Fifty-eight patients were found to have no evidence of disease (NED) and chemotherapy was discontinued. Eight patients with advanced ovarian cancer had NED 5 or more years after negative second-look operations and were probably cured by chemotherapy. Seven patients who were found to have cancer at second-look operations had a change in management as a result of the operation and had NED 5 or more years later. The most important factors correlating with negative second-look operations were the stage of cancer, the amount of residual tumor left at the initial operation, and the number of courses of chemotherapy administered prior to the second-look operation. Survival after positive second-look operations varied directly with the volume of tumor found at the time of operation and the amount of tumor left behind at the second-look operation. Patients who were treated with radiation therapy had a poorer survival rate than those who were treated with chemotherapy after positive second-look operations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7446620     DOI: 10.1016/s0002-9378(16)32778-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  Second-look laparotomy for epithelial ovarian cancer: a reappraisal.

Authors:  C S Chu; S C Rubin
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay.

Authors:  J A Ajani; B Tomasovic; G Spitzer; J J Kavanagh; D Thielvoldt; F L Baker; D Gershenson
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

3.  Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.

Authors:  W Jäger; R Adam; L Wildt; N Lang
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

Review 4.  Complications of gynaecological cancer surgery: a review.

Authors:  J H Shepherd; M E Crowther
Journal:  J R Soc Med       Date:  1986-05       Impact factor: 5.344

5.  Whole-abdomen radiation in patients with advanced ovarian carcinoma after surgery, chemotherapy, and second-look laparotomy.

Authors:  R Greiner; A Goldhirsch; B W Davis; E Dreher; T Peyer; G Locher; H Neuenschwander; R Joss; K Brunner; P Veraguth
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

6.  Long-term survival in stage III and IV ovarian cancer.

Authors:  E Petru; B U Sevin; H E Averette; O R Koechli; S Hilsenbeck
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

7.  Recent progress in the treatment of epithelial ovarian malignancy.

Authors:  J S Berek; N F Hacker; L D Lagasse
Journal:  West J Med       Date:  1982-10

8.  Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.

Authors:  C Sessa; G Bolis; N Colombo; M D'Incalci; B Mermillod; I Valente; C Mangioni
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Second look laparotomy in the management of epithelial cell carcinoma of the ovary.

Authors:  G M Mead; C J Williams; F R MacBeth; I E Boyd; J M Whitehouse
Journal:  Br J Cancer       Date:  1984-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.